{
    "clinical_study": {
        "@rank": "63673", 
        "acronym": "FMG-MM02", 
        "arm_group": [
            {
                "arm_group_label": "A", 
                "arm_group_type": "Active Comparator", 
                "description": "Cyclophosphamide plus filgrastim"
            }, 
            {
                "arm_group_label": "B", 
                "arm_group_type": "Active Comparator", 
                "description": "Filgrastim"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determinate the efficacy and safety of the 3-drug induction\n      treatment (RVD; lenalidomide plus bortezomib plus dexamethasone)followed by randomized\n      autologous stem cell mobilization, autologous stem cell transplantation and lenalidomide\n      maintenance. Primary endpoint is the  immunophenotypic remission rate.During the randomized\n      mobilization phase two active comparator arms Cyclophosphamide (CY)2g/m2 +\n      Granylocyte-colony stimulating factor)G-CSF vrs G-CSF will be compared regarding efficacy,\n      costs and safety."
        }, 
        "brief_title": "First Line Treatment Trial in Multiple Myeloma, Finnish Myeloma Group- Multiple Myeloma 02", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Multiple Myeloma", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  written informed consent\n\n          -  symptomatic, previously untreated International Stating System (ISS) 1-3 myeloma\n\n          -  measurable disease\n\n          -  WHO perf status 0-3\n\n          -  eligible for ASCT\n\n        Exclusion Criteria:\n\n          -  previously treated\n\n          -  peripheral neuropathy gr >/= 2\n\n          -  significant hepatic dysfunction\n\n          -  severe cardiac dysfunction\n\n          -  severe renal failure if not in dialysis"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01790737", 
            "org_study_id": "KUH5101424", 
            "secondary_id": "2012-001051-39"
        }, 
        "intervention": [
            {
                "arm_group_label": "A", 
                "intervention_name": "Cyclophosphamide", 
                "intervention_type": "Drug", 
                "other_name": "Cyclophosphamide"
            }, 
            {
                "arm_group_label": "B", 
                "intervention_name": "Filgrastim", 
                "intervention_type": "Drug", 
                "other_name": "Filgrastim"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclophosphamide", 
                "Lenograstim"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "myeloma, stem cell mobilization, autologous stem cell transplantation", 
            "induction treatment, maintenance treatment"
        ], 
        "lastchanged_date": "August 12, 2013", 
        "location": [
            {
                "contact": {
                    "email": "raija.silvennoinen@kuh.fi", 
                    "last_name": "Raija H Silvennoinen, MD", 
                    "phone": "+358447176075"
                }, 
                "contact_backup": {
                    "email": "esa.jantunen@kuh.fi", 
                    "last_name": "Esa Jantunen, MD, PhD", 
                    "phone": "+358447172569"
                }, 
                "facility": {
                    "address": {
                        "city": "Kuopio", 
                        "country": "Finland", 
                        "state": "North Savo", 
                        "zip": "70200"
                    }, 
                    "name": "Kuopio University Hospital"
                }, 
                "investigator": [
                    {
                        "last_name": "Raija H Silvennoinen, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Esa Jantunen, MD,PhD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Tapio Nousiainen, MD,PhD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Taru Kuittinen, MD,PhD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Marja Py\u00f6r\u00e4l\u00e4, MD,PhD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tampere", 
                        "country": "Finland", 
                        "state": "Pirkanmaa", 
                        "zip": "33100"
                    }, 
                    "name": "Tampere University Hospital"
                }, 
                "status": "Active, not recruiting"
            }
        ], 
        "location_countries": {
            "country": "Finland"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Prospective Phase II Study to Assess Immunophenotypic Remission After 3-drug Induction Followed by Randomized Stem Cell Mobilization, Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma", 
        "other_outcome": {
            "measure": "Proportion of pts collected with > 3 x 10e6/kg CD34+ with </= 2 apheresis after mobilization with CY 2g/m2 + filgrastim (group A) or filgrastim alone (group B)", 
            "safety_issue": "Yes", 
            "time_frame": "Assessed up to 2 weeks from the start of mobilization"
        }, 
        "overall_contact": {
            "email": "raija.silvennoinen@kuh.fi", 
            "last_name": "Raija H Silvennoinen, MD", 
            "phone": "+358447176075"
        }, 
        "overall_contact_backup": {
            "email": "esa.jantunen@kuh.fi", 
            "last_name": "Esa Jantunen, MD,PhD", 
            "phone": "+358447176075"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Finland: Finnish Medicines Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Response will be measured by International Myeloma Working Group (IMWG) guidelines, and if the response is stringent CR and immunophenotypic remission, those patients will be followed also by allele-spesific oligonucleotide-polymerase chain reaction assay (ASO-PCR) to find out molecular remission rate.", 
            "measure": "Immunophenotypic response", 
            "safety_issue": "Yes", 
            "time_frame": "Change from the start of induction treatment at 3 months, change from the start of induction at 6 months, at 9 months, at 12 months,  at 16 months,  at 20 months, at 24 moths"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01790737"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Progression free survival", 
            "safety_issue": "Yes", 
            "time_frame": "From date of inclusion until the date of first documented progression or date of death from any cause whatever come first assessed up to laste patient 2 years on maintenance"
        }, 
        "source": "Kuopio University Hospital", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Helsinki University Central Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Tampere University Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Turku University Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Oulu University Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Mikkeli Central Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Kymenlaakso Central Hospital Kotka Finland", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Jyv\u00e4skyl\u00e4 Central Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Seinajoki Central Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Paijat-Hame Hospital District", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Central Hospital of Kanta-Hame", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Satakunta Central Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Kainuu and L\u00e4nsi-Pohja Central Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Celgene Corporation", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Kuopio University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}